The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans

Joseph Cheriyan, Timothy J. Burton, Timothy J. Bradley, Sharon M. L. Wallace, Kaisa M. Mäki-Petäjä, Isla S. MacKenzie, Carmel M. McEniery, John Brown, Ian B. Wilkinson

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Aims: (i) To compare the effects of intra-arterial administration of urotensin II in patients with CVD with healthy volunteers, and (ii) to study the haemodynamic effects of intra-arterial infusion of the urotensin II receptor antagonist, urantide. Methods: Ten healthy volunteers and 10 patients with CVD received a dose-ramped brachial artery infusion of urotensin II. A further six healthy male volunteers received a prolonged urotensin II infusion and 11 healthy male volunteers received a dose-ramped infusion of urantide. Forearm blood flow (FBF) was measured every 20 min and blood pressure and heart rate were assessed every 20 min. Results: In healthy volunteers and patients with CVD, intra-arterial infusion of urotensin II had no effect on FBF ratio. A dose-ramped infusion of urantide similarly had no effect on FBF ratio. During dose-ramped infusions of urotensin II and urantide, systolic and mean arterial blood pressure increased significantly. In healthy volunteers, urotensin II and urantide, respectively, increased systolic blood pressure from 133 ± 6 to 137 ± 5 mmHg (P <0.01) and from 113 ± 4 to 120 ± 4 mmHg (P <0.01). In patients with CVD, heart rate also significantly increased during dose-ramped infusion of urotensin II from 59 ± 3 to 62 ± 4 bpm (P <0.05). Conclusions: We have shown no in vivo effect of urotensin II or urantide on human forearm resistance vessels. Previous discrepancies do not seem to relate to either the age or CVD status of subjects. Changes in systemic cardiovascular haemodynamics during the dose-ramped infusion studies are unlikely to be caused by urotensin II receptor modulation.
    Original languageEnglish
    Pages (from-to)518-523
    Number of pages6
    JournalBritish Journal of Clinical Pharmacology
    Volume68
    Issue number4
    DOIs
    Publication statusPublished - 1 Oct 2009

    Fingerprint

    Forearm
    Hemodynamics
    Healthy Volunteers
    Intra Arterial Infusions
    Blood Pressure
    Arterial Pressure
    Heart Rate
    Pen(5)-Trp(7)-Orn(8)-urotensin II (4-11)
    urotensin II
    Brachial Artery

    Cite this

    Cheriyan, Joseph ; Burton, Timothy J. ; Bradley, Timothy J. ; Wallace, Sharon M. L. ; Mäki-Petäjä, Kaisa M. ; MacKenzie, Isla S. ; McEniery, Carmel M. ; Brown, John ; Wilkinson, Ian B. / The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. In: British Journal of Clinical Pharmacology. 2009 ; Vol. 68, No. 4. pp. 518-523.
    @article{c1254cb32f324ce7b3fffeb8f0bfcf56,
    title = "The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans",
    abstract = "Aims: (i) To compare the effects of intra-arterial administration of urotensin II in patients with CVD with healthy volunteers, and (ii) to study the haemodynamic effects of intra-arterial infusion of the urotensin II receptor antagonist, urantide. Methods: Ten healthy volunteers and 10 patients with CVD received a dose-ramped brachial artery infusion of urotensin II. A further six healthy male volunteers received a prolonged urotensin II infusion and 11 healthy male volunteers received a dose-ramped infusion of urantide. Forearm blood flow (FBF) was measured every 20 min and blood pressure and heart rate were assessed every 20 min. Results: In healthy volunteers and patients with CVD, intra-arterial infusion of urotensin II had no effect on FBF ratio. A dose-ramped infusion of urantide similarly had no effect on FBF ratio. During dose-ramped infusions of urotensin II and urantide, systolic and mean arterial blood pressure increased significantly. In healthy volunteers, urotensin II and urantide, respectively, increased systolic blood pressure from 133 ± 6 to 137 ± 5 mmHg (P <0.01) and from 113 ± 4 to 120 ± 4 mmHg (P <0.01). In patients with CVD, heart rate also significantly increased during dose-ramped infusion of urotensin II from 59 ± 3 to 62 ± 4 bpm (P <0.05). Conclusions: We have shown no in vivo effect of urotensin II or urantide on human forearm resistance vessels. Previous discrepancies do not seem to relate to either the age or CVD status of subjects. Changes in systemic cardiovascular haemodynamics during the dose-ramped infusion studies are unlikely to be caused by urotensin II receptor modulation.",
    author = "Joseph Cheriyan and Burton, {Timothy J.} and Bradley, {Timothy J.} and Wallace, {Sharon M. L.} and M{\"a}ki-Pet{\"a}j{\"a}, {Kaisa M.} and MacKenzie, {Isla S.} and McEniery, {Carmel M.} and John Brown and Wilkinson, {Ian B.}",
    note = "MEDLINE{\circledR} is the source for the MeSH terms of this document.",
    year = "2009",
    month = "10",
    day = "1",
    doi = "10.1111/j.1365-2125.2009.03475.x",
    language = "English",
    volume = "68",
    pages = "518--523",
    journal = "British Journal of Clinical Pharmacology",
    issn = "0306-5251",
    publisher = "Wiley",
    number = "4",

    }

    Cheriyan, J, Burton, TJ, Bradley, TJ, Wallace, SML, Mäki-Petäjä, KM, MacKenzie, IS, McEniery, CM, Brown, J & Wilkinson, IB 2009, 'The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans', British Journal of Clinical Pharmacology, vol. 68, no. 4, pp. 518-523. https://doi.org/10.1111/j.1365-2125.2009.03475.x

    The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. / Cheriyan, Joseph; Burton, Timothy J.; Bradley, Timothy J.; Wallace, Sharon M. L.; Mäki-Petäjä, Kaisa M.; MacKenzie, Isla S.; McEniery, Carmel M.; Brown, John ; Wilkinson, Ian B.

    In: British Journal of Clinical Pharmacology, Vol. 68, No. 4, 01.10.2009, p. 518-523.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans

    AU - Cheriyan, Joseph

    AU - Burton, Timothy J.

    AU - Bradley, Timothy J.

    AU - Wallace, Sharon M. L.

    AU - Mäki-Petäjä, Kaisa M.

    AU - MacKenzie, Isla S.

    AU - McEniery, Carmel M.

    AU - Brown, John

    AU - Wilkinson, Ian B.

    N1 - MEDLINE® is the source for the MeSH terms of this document.

    PY - 2009/10/1

    Y1 - 2009/10/1

    N2 - Aims: (i) To compare the effects of intra-arterial administration of urotensin II in patients with CVD with healthy volunteers, and (ii) to study the haemodynamic effects of intra-arterial infusion of the urotensin II receptor antagonist, urantide. Methods: Ten healthy volunteers and 10 patients with CVD received a dose-ramped brachial artery infusion of urotensin II. A further six healthy male volunteers received a prolonged urotensin II infusion and 11 healthy male volunteers received a dose-ramped infusion of urantide. Forearm blood flow (FBF) was measured every 20 min and blood pressure and heart rate were assessed every 20 min. Results: In healthy volunteers and patients with CVD, intra-arterial infusion of urotensin II had no effect on FBF ratio. A dose-ramped infusion of urantide similarly had no effect on FBF ratio. During dose-ramped infusions of urotensin II and urantide, systolic and mean arterial blood pressure increased significantly. In healthy volunteers, urotensin II and urantide, respectively, increased systolic blood pressure from 133 ± 6 to 137 ± 5 mmHg (P <0.01) and from 113 ± 4 to 120 ± 4 mmHg (P <0.01). In patients with CVD, heart rate also significantly increased during dose-ramped infusion of urotensin II from 59 ± 3 to 62 ± 4 bpm (P <0.05). Conclusions: We have shown no in vivo effect of urotensin II or urantide on human forearm resistance vessels. Previous discrepancies do not seem to relate to either the age or CVD status of subjects. Changes in systemic cardiovascular haemodynamics during the dose-ramped infusion studies are unlikely to be caused by urotensin II receptor modulation.

    AB - Aims: (i) To compare the effects of intra-arterial administration of urotensin II in patients with CVD with healthy volunteers, and (ii) to study the haemodynamic effects of intra-arterial infusion of the urotensin II receptor antagonist, urantide. Methods: Ten healthy volunteers and 10 patients with CVD received a dose-ramped brachial artery infusion of urotensin II. A further six healthy male volunteers received a prolonged urotensin II infusion and 11 healthy male volunteers received a dose-ramped infusion of urantide. Forearm blood flow (FBF) was measured every 20 min and blood pressure and heart rate were assessed every 20 min. Results: In healthy volunteers and patients with CVD, intra-arterial infusion of urotensin II had no effect on FBF ratio. A dose-ramped infusion of urantide similarly had no effect on FBF ratio. During dose-ramped infusions of urotensin II and urantide, systolic and mean arterial blood pressure increased significantly. In healthy volunteers, urotensin II and urantide, respectively, increased systolic blood pressure from 133 ± 6 to 137 ± 5 mmHg (P <0.01) and from 113 ± 4 to 120 ± 4 mmHg (P <0.01). In patients with CVD, heart rate also significantly increased during dose-ramped infusion of urotensin II from 59 ± 3 to 62 ± 4 bpm (P <0.05). Conclusions: We have shown no in vivo effect of urotensin II or urantide on human forearm resistance vessels. Previous discrepancies do not seem to relate to either the age or CVD status of subjects. Changes in systemic cardiovascular haemodynamics during the dose-ramped infusion studies are unlikely to be caused by urotensin II receptor modulation.

    UR - http://www.scopus.com/inward/record.url?scp=70449112887&partnerID=8YFLogxK

    U2 - 10.1111/j.1365-2125.2009.03475.x

    DO - 10.1111/j.1365-2125.2009.03475.x

    M3 - Article

    VL - 68

    SP - 518

    EP - 523

    JO - British Journal of Clinical Pharmacology

    JF - British Journal of Clinical Pharmacology

    SN - 0306-5251

    IS - 4

    ER -